Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

A sub-study of belantamab mafodotin in combination with feladilimab in relapsed/refractory multiple myeloma is being conducted in Phase 1/Phase 2, with the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• Feladilimab (feladilimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING